我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
0
0 进行中
药物批准
批准总数
监管机构
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无批准数据
• The Noramco Group is investing $25 million in its Halo Pharma facility in Whippany, New Jersey to establish sterile injectable manufacturing capabilities, addressing critical capacity shortages in the US supply chain. • The expansion includes installation of a high-speed Groninger UFVN FlexFill filling line and SKAN isolator, with annual production capacity exceeding 50 million units for syringes, cartridges, and vials. • The new sterile manufacturing line is expected to be qualified and operational within 12 months, with facility upgrades meeting both US quality standards and EU Annex 1 compliance for European market access.
